12
Jan

Oncology biotech Mersana Therapeutics has expanded its relationship with Takeda, forging an agreement to develop targeted cancer drugs with as much as $300 million on the line.

…read more

Source: Mersana lines up for $300M in an R&D deal with Takeda

    

0 No comments